The latest biotech news

News and Trends 3 Aug 2022

Chinese biotech Sironax closes $200M funding round

Sironax, an emerging Chinese biotechnology company dedicated to the discovery and global development of novel treatments for patients with age-related degenerative diseases, has completed $200 million in series B financing. The round was led by Gaorong Capital and Yunfeng Capital, with participation from existing investors including Temasek, Invus, F-Prime Capital, Eight Roads, ARCH Venture Partners, […]

August 3, 2022 - 3 minutesmins - By Jim Cornall

More News! 3 Aug 2022

Orca Bio announces Precision-T phase 3 study open and enrolling patients across US transplant centers

US-based Orca Bio, today announced Precision-T, its pivotal phase 3 study, is open, enrolling and treating 174 leukemia patients at more than 20 clinical trial sites. Precision-T is a randomized, open-label multi-center study that is evaluating the safety and efficacy of Orca Bio’s lead investigational high-precision cell therapy, Orca-T, compared to standard of care allogeneic […]

August 3, 2022 - 2 minutesmins - By Liza Laws

News and Trends 3 Aug 2022

siRNA company Eleven Therapeutics seals $22M funding

Eleven Therapeutics has raised a total of $22 million in seed funding. Among the roster of funders is the Bill & Melinda Gates Foundation, which committed $9 million in funding to Eleven, including $5 million towards future equity investment supporting the development of a first-of-its-kind platform that designs small interfering RNAs (siRNAs) with ultra-long durability […]

August 3, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 2 Aug 2022

Enrollment completed for trial looking at treatment of diabetic kidney disease

Enrollment has been completed for a study of a regenerative cell therapy investigational product for intra-renal artery administration to treat diabetic kidney disease (DKD). U.S.-based Caladrius Biosciences Inc., a clinical-stage biopharma company that develops therapies designed to treat or reverse disease, made the announcement today (August 2). The phase 1b open-label, proof-of-concept study will look […]

August 2, 2022 - 2 minutesmins - By Liza Laws

News and Trends 2 Aug 2022

New monkeypox tracing method can analyze multiple samples and quickly detect virus strains

Dutch company Molecular Biology Systems (MBS), in collaboration with Amsterdam University Medical Center, and researchers from the Danish Rigshospitalet, has developed a fast typing method to trace monkeypox. The new method, NextGenPCR, not only detects strains of the virus quickly, it allows for analysis of multiple samples simultaneously. This way, the inventors say, genetic characterization […]

August 2, 2022 - 3 minutesmins - By Liza Laws

News and Trends 2 Aug 2022

Success across the board for C4X Discovery Holdings plc and its partnerships

Drug discovery company C4X Discovery Holdings plc released a report today (August 2) detailing the continued success of its relationship with partners across its portfolio. The company says it is happy to report it received its first milestone payment last month of €3 million ($3.1 million) from Sanofi under the out-licensing agreement for its IL-17A […]

August 2, 2022 - 3 minutesmins - By Liza Laws

News and Trends 2 Aug 2022

MAIA Biotechnology raises $10M from public offering

U.S. clinical stage company MAIA Biotechnology, Inc. has closed its initial public offering of 2,000,000 shares of the company’s common stock at a public offering price of $5.00 per share. The gross proceeds from the initial public offering were $10 million, prior to deducting underwriting discounts, commissions, and other offering expenses. The company has granted […]

August 2, 2022 - 2 minutesmins - By Jim Cornall

cancer shutterstock immunotherapy deep science ventures

News and Trends 2 Aug 2022

IDRx launches with $122M to treat cancer with precision combination therapies

DRx, Inc., a clinical-stage biopharmaceutical company, launched today with a $122 million oversubscribed series A financing. The financing was led by Andreessen Horowitz (a16z) and Casdin Capital, with participation from Nextech Invest, Forge Life Science Partners and other undisclosed investors. Inspired by a few curative combination regimens in cancer and the successful drug cocktails engineered […]

August 2, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 2 Aug 2022

FDA gives ok to Krystal Biotech cystic fibrosis clinical trial

U.S. company Krystal Biotech is set to start a clinical trial for cystic fibrosis after the United States Food and Drug Administration (FDA) accepted its investigational new drug (IND) application. The gene therapy company will be evaluating KB407, a modified HSV-1 vector carrying two copies of the cystic fibrosis transmembrane conductance regulator (CFTR) gene to […]

August 2, 2022 - 3 minutesmins - By Jim Cornall

Sanofi drops amcenestrant clinical development program

News and Trends 2 Aug 2022

Defence Therapeutics says AccuTOX kills cancer cells

Defence Therapeutics Inc., a Canadian biopharma company specializing in immune-oncology vaccines and drug delivery technologies, says it has discovered a novel DNA damaging function triggered by one of its lead compounds AccuTOX, which effectively elicits cell death in cancer cells. Cancer can be generally described as a state of uncontrolled cell proliferation. This is mainly […]

August 2, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 2 Aug 2022

Glycostem and medac sign deal on AML and MM product

Glycostem Therapeutics B.V. and medac GmbH are to partner to commercialize Glycostem’s lead product, oNKord. oNKord is currently in a phase 1/2 clinical trial across 10 hospitals in five European countries. Glycostem is a Dutch clinical-stage company focused on the development of therapeutic allogeneic off-the-shelf natural killer (NK) cells, and medac is an international pharmaceutical […]

August 2, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 2 Aug 2022

Cellectis gets green light for non-Hodgkin lymphoma trial

French-headquartered gene-editing biotech company Cellectis says the U.S. Food and Drug Administration (FDA) has cleared Cellectis’ Investigational New Drug (IND) application to initiate a phase 1/2a clinical trial of UCART20x22 for patients with relapsed or refractory non-Hodgkin lymphoma (r/r NHL). The company plans to begin enrolling patients in the NatHaLi-01 study in the second half […]

August 2, 2022 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Chinese biotech Sironax closes $200M funding round

Orca Bio announces Precision-T phase 3 study open and enrolling patients across US transplant centers

siRNA company Eleven Therapeutics seals $22M funding

Enrollment completed for trial looking at treatment of diabetic kidney disease

New monkeypox tracing method can analyze multiple samples and quickly detect virus strains

Success across the board for C4X Discovery Holdings plc and its partnerships

MAIA Biotechnology raises $10M from public offering

IDRx launches with $122M to treat cancer with precision combination therapies

FDA gives ok to Krystal Biotech cystic fibrosis clinical trial

Defence Therapeutics says AccuTOX kills cancer cells

Glycostem and medac sign deal on AML and MM product

Cellectis gets green light for non-Hodgkin lymphoma trial

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!